Table 4.
Covariates* | HR (95% CI) | P trend |
---|---|---|
Estradiol, pg/mL | ||
<8 | 1.00 (referent) | |
≥8 | 1.52 (1.02 to 2.26) | .040 |
Insulin, μIU/mL | ||
≤3.3 | 1.00 (referent) | .003 |
3.4–5.3 | 1.20 (0.69 to 2.07) | |
5.4–8.5 | 1.60 (0.93 to 2.73) | |
≥8.6 | 2.37 (1.30 to 4.30) | |
CRP, μg/mL | ||
≤0.91 | 1.00 (referent) | .029 |
0.92–2.01 | 0.98 (0.63 to 1.54) | |
≥2.02 | 1.67 (1.04 to 2.68) |
*Multivariable model included estradiol, insulin, C-reactive protein, and the following covariates: age, race/ethnicity, body mass index, alcohol consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth, history of benign breast disease, and physical activity. All statistical tests were two-sided. CI = confidence interval; CRP = C-reactive protein; HR = hazard ratio; HT = hormone therapy.